Abstract: A waste management system includes a waste management device, a monitoring unit, and a communication unit. The waste management device includes a collection unit, a classification unit, a segregation unit, a plurality of sensors, a power unit, and a plurality of waste bins. The collection unit collects one or more waste articles. The classification unit utilizes a machine-learning model and identifies a waste category of the one or more waste articles. The segregation unit transports the one or more waste articles to a particular waste bin corresponding to the identified waste category. The power unit supplies power to the waste management device. The monitoring unit monitors the waste management device and controls a resultant action. The communication unit communicates one or more data between a control station and the waste management device using a plurality of IoT devices.

Abstract: The self-regenerated and eco-friendly air purification device uses an adsorption material retained in a housing, the adsorption material capable of adsorption of carbon dioxide. A fan causes air to flow over the adsorption material, thereby extracting excess carbon dioxide from room air at room temperature. A heater is provided, and activation of the heater causes discharge of the adsorbed carbon dioxide from the adsorption material, thereby regenerating the adsorption material to adsorb more carbon dioxide. In one configuration, the adsorption material includes activated carbon (or any other CO2 adsorbent) and is capable of adsorption of carbon dioxide (CO2), and activation of the heater causes discharge of the CO2 adsorbed by the adsorption material.

Abstract: Systems and methods for separating a mixture of olefinic and paraffinic C4 components are disclosed. The systems and methods include adsorptive equipment and adsorptive processes for separating components from the mixture.

Abstract: The ocean thermal and hydraulic energy conversion system includes a closed loop assembly comprising a pipeline filled with a working fluid, a pump and a turbine. The system includes a first supply line to transport warm water to an evaporator and then to a junction, and a second supply line to transport cold water to a condenser and then to the junction. The evaporator evaporates the working fluid from a liquid into a vapor using the warm water and the vapor powers the turbine. A generator is connected to the turbine and generates electricity by the powered turbine. The condenser condenses the working fluid vapor to a liquid using the cold water. A hydraulic converter receives the warm and cold water from the junction and converts the hydraulic energy into electricity.

Abstract: The ocean thermal and hydraulic energy conversion system includes a closed loop assembly comprising a pipeline filled with a working fluid, a pump and a turbine. The system includes a first supply line to transport warm water to an evaporator and then to a junction, and a second supply line to transport cold water to a condenser and then to the junction. The evaporator evaporates the working fluid from a liquid into a vapor using the warm water and the vapor powers the turbine. A generator is connected to the turbine and generates electricity by the powered turbine. The condenser condenses the working fluid vapor to a liquid using the cold water. A hydraulic converter receives the warm and cold water from the junction and converts the hydraulic energy into electricity.

Abstract: A ribonucleoprotein (RNP) delivery system comprising (a) a cationic lipid; (b) a phospholipid; (c) a peptide of the structure A-B-C in which A is a polycationic nucleic acid-binding component, B is a spacer element comprising two or more amino acid residues, and C is a cell surface receptor binding component; and (d) a ribonucleoprotein (RNP) complex comprising a CRISPR-associated protein and guide RNA, pharmaceutical compositions comprising such a ribonucleoprotein (RNP) delivery system, and methods for the treatment or prophylaxis of a condition caused in a human or in a non-human animal by a defect and/or a deficiency in a gene, or for RNA therapy, or for the treatment of a cancer, which comprises administering the RNP delivery system or pharmaceutical composition to the human or to the non-human animal.